S&P 500   3,329.35 (+0.26%)
DOW   29,228.32 (+0.11%)
QQQ   224.75 (+0.66%)
AAPL   319.24 (+0.84%)
FB   222.33 (+0.40%)
MSFT   166.50 (+0.00%)
GOOGL   1,492.31 (+0.68%)
AMZN   1,894.19 (+0.12%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.92 (+7.44%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.11%)
NFLX   329.47 (-2.56%)
BAC   34.30 (+0.12%)
DIS   144.00 (+0.31%)
GILD   63.10 (+0.75%)
S&P 500   3,329.35 (+0.26%)
DOW   29,228.32 (+0.11%)
QQQ   224.75 (+0.66%)
AAPL   319.24 (+0.84%)
FB   222.33 (+0.40%)
MSFT   166.50 (+0.00%)
GOOGL   1,492.31 (+0.68%)
AMZN   1,894.19 (+0.12%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.92 (+7.44%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.11%)
NFLX   329.47 (-2.56%)
BAC   34.30 (+0.12%)
DIS   144.00 (+0.31%)
GILD   63.10 (+0.75%)
S&P 500   3,329.35 (+0.26%)
DOW   29,228.32 (+0.11%)
QQQ   224.75 (+0.66%)
AAPL   319.24 (+0.84%)
FB   222.33 (+0.40%)
MSFT   166.50 (+0.00%)
GOOGL   1,492.31 (+0.68%)
AMZN   1,894.19 (+0.12%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.92 (+7.44%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.11%)
NFLX   329.47 (-2.56%)
BAC   34.30 (+0.12%)
DIS   144.00 (+0.31%)
GILD   63.10 (+0.75%)
S&P 500   3,329.35 (+0.26%)
DOW   29,228.32 (+0.11%)
QQQ   224.75 (+0.66%)
AAPL   319.24 (+0.84%)
FB   222.33 (+0.40%)
MSFT   166.50 (+0.00%)
GOOGL   1,492.31 (+0.68%)
AMZN   1,894.19 (+0.12%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.92 (+7.44%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.11%)
NFLX   329.47 (-2.56%)
BAC   34.30 (+0.12%)
DIS   144.00 (+0.31%)
GILD   63.10 (+0.75%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NYSE:MKC - MCCORMICK & CO /SH Stock Price, Forecast & News

$172.98
+1.83 (+1.07 %)
(As of 01/22/2020 01:10 PM ET)
Add
Compare
Today's Range
$171.58
Now: $172.98▼
$173.01
50-Day Range
$162.24
MA: $168.81▼
$172.50
52-Week Range
$119.00
Now: $172.98▼
$173.31
Volume7,759 shs
Average Volume607,736 shs
Market Capitalization$22.99 billion
P/E Ratio32.89
Dividend Yield1.47%
Beta0.13
McCormick & Company, Incorporated manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavorful products to the food industry. The company operates in two segments, Consumer and Flavor Solutions. The Consumer segment offers spices, herbs, and seasonings, as well as desserts. This segment markets its products under the McCormick, French, Frank's RedHot, Lawry's, Club House, Gourmet Garden, and OLD BAY brands in the Americas; Ducros, Schwartz, Kamis, and Drogheria & Alimentari, and Vahiné brand names in Europe, the Middle East, and Africa; McCormick and DaQiao brands in China; and McCormick, Aeroplane, and Gourmet Garden brand names in Australia, as well as markets regional and ethnic brands, such as Zatarain's, Stubb's, Thai Kitchen, and Simply Asia. Read More…

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPackaged Foods & Meats
SectorConsumer Staples
Current SymbolNYSE:MKC
Previous Symbol
CUSIP57978020
CIK63754
Webhttp://www.mccormickcorporation.com/
Phone410-771-7301

Debt

Debt-to-Equity Ratio1.10
Current Ratio0.78
Quick Ratio0.37

Price-To-Earnings

Trailing P/E Ratio32.89
Forward P/E Ratio32.21
P/E Growth4.3

Sales & Book Value

Annual Sales$5.41 billion
Price / Sales4.25
Cash Flow$6.31 per share
Price / Cash Flow27.42
Book Value$24.09 per share
Price / Book7.18

Profitability

EPS (Most Recent Fiscal Year)$4.97
Net Income$933.40 million
Net Margins13.12%
Return on Equity21.63%
Return on Assets7.05%

Miscellaneous

Employees14,400
Outstanding Shares132,910,000
Market Cap$22.99 billion
Next Earnings Date1/28/2020 (Confirmed)
OptionableOptionable

Receive MKC News and Ratings via Email

Sign-up to receive the latest news and ratings for MKC and its competitors with MarketBeat's FREE daily newsletter.

MKC Rates by TradingView

(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

MCCORMICK & CO /SH (NYSE:MKC) Frequently Asked Questions

What is MCCORMICK & CO /SH's stock symbol?

MCCORMICK & CO /SH trades on the New York Stock Exchange (NYSE) under the ticker symbol "MKC."

How often does MCCORMICK & CO /SH pay dividends? What is the dividend yield for MCCORMICK & CO /SH?

MCCORMICK & CO /SH announced a quarterly dividend on Tuesday, November 26th. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.62 per share on Monday, January 13th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 1.43%. The ex-dividend date is Monday, December 30th. This is an increase from MCCORMICK & CO /SH's previous quarterly dividend of $0.57. View MCCORMICK & CO /SH's Dividend History.

How were MCCORMICK & CO /SH's earnings last quarter?

MCCORMICK & CO /SH NV (NYSE:MKC) released its quarterly earnings data on Tuesday, October, 1st. The company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.17. The business earned $1.33 billion during the quarter, compared to analysts' expectations of $1.34 billion. MCCORMICK & CO /SH had a net margin of 13.12% and a return on equity of 21.63%. The business's quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the firm earned $1.28 earnings per share. View MCCORMICK & CO /SH's Earnings History.

When is MCCORMICK & CO /SH's next earnings date?

MCCORMICK & CO /SH is scheduled to release their next quarterly earnings announcement on Tuesday, January 28th 2020. View Earnings Estimates for MCCORMICK & CO /SH.

How can I listen to MCCORMICK & CO /SH's earnings call?

MCCORMICK & CO /SH will be holding an earnings conference call on Tuesday, January 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for MKC?

9 analysts have issued 1 year price targets for MCCORMICK & CO /SH's stock. Their forecasts range from $140.00 to $172.00. On average, they anticipate MCCORMICK & CO /SH's stock price to reach $156.00 in the next year. This suggests that the stock has a possible downside of 9.8%. View Analyst Price Targets for MCCORMICK & CO /SH.

What is the consensus analysts' recommendation for MCCORMICK & CO /SH?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MCCORMICK & CO /SH in the last year. There are currently 3 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MCCORMICK & CO /SH.

What are Wall Street analysts saying about MCCORMICK & CO /SH stock?

Here are some recent quotes from research analysts about MCCORMICK & CO /SH stock:
  • 1. According to Zacks Investment Research, "McCormick has outperformed the industry in the past three months, largely driven by its robust-savings initiatives and sales-driving efforts. These factors fueled first-quarter fiscal 2019 results, wherein earnings improved year on year and surpassed the Zacks Consensus Estimate. Also, the top line remained sturdy, gaining from a strong base business as well as new product developments. New launches under the Frank's and French's banners have been yielding results. Notably, the company is on track with new product developments across different categories for fiscal 2019. Also, it is progressing well with augmenting digital marketing efforts. On the flip side, we note that adverse currency fluctuations were a drag on the top and the bottom line during the first quarter. Management expects such headwinds to persist in fiscal 2019." (5/30/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "Results are not directly comparable to our estimates given the adoption of new accounting standards, however, organic sales growth was better than expected, gross margins were flat y/y and EBIT was generally in line. Expectations were high and although 1Q was solid, quality was not high enough, in our view." (3/26/2019)

Has MCCORMICK & CO /SH been receiving favorable news coverage?

News coverage about MKC stock has trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MCCORMICK & CO /SH earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for MCCORMICK & CO /SH.

Who are some of MCCORMICK & CO /SH's key competitors?

What other stocks do shareholders of MCCORMICK & CO /SH own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MCCORMICK & CO /SH investors own include Johnson & Johnson (JNJ), AT&T (T), Mcdonald's (MCD), Starbucks (SBUX), Home Depot (HD), PepsiCo (PEP), Walt Disney (DIS), Medtronic (MDT), NVIDIA (NVDA) and AbbVie (ABBV).

Who are MCCORMICK & CO /SH's key executives?

MCCORMICK & CO /SH's management team includes the folowing people:
  • Mr. Lawrence E. Kurzius, Chairman, Pres & CEO (Age 61)
  • Mr. Michael R. Smith, Exec. VP & CFO (Age 54)
  • Mr. Jeffery D. Schwartz, VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. Malcolm S. Swift, Pres of Global Flavor Solutions & McCormick International (Age 59)
  • Mr. Brendan F. Foley, Pres of Global Consumer & Americas (Age 53)

Who are MCCORMICK & CO /SH's major shareholders?

MCCORMICK & CO /SH's stock is owned by many different of retail and institutional investors. Top institutional investors include Huntington National Bank (0.22%), Boston Trust Walden Corp (0.11%), Wendell David Associates Inc. (0.09%), Commerzbank Aktiengesellschaft FI (0.09%), Stock Yards Bank & Trust Co. (0.08%) and Bath Savings Trust Co (0.07%). Company insiders that own MCCORMICK & CO /SH stock include Alan D Wilson, Christina M Mcmullen, Jacques Tapiero, Lawrence Erik Kurzius, Lisa Manzone, Malcolm Swift, Margaret M V Preston, Michael Aaron Conway, Michael D Mangan, Michael R Smith, Nneka Louise Rimmer and Patricia A Little. View Institutional Ownership Trends for MCCORMICK & CO /SH.

Which major investors are selling MCCORMICK & CO /SH stock?

MKC stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Sciencast Management LP, Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, Nisa Investment Advisors LLC, Boston Trust Walden Corp, Assenagon Asset Management S.A. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold MCCORMICK & CO /SH company stock in the last year include Alan D Wilson, Christina M Mcmullen, Jacques Tapiero, Lisa Manzone, Malcolm Swift, Margaret M V Preston, Michael Aaron Conway, Michael R Smith and Nneka Louise Rimmer. View Insider Buying and Selling for MCCORMICK & CO /SH.

Which major investors are buying MCCORMICK & CO /SH stock?

MKC stock was acquired by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Mainstay Capital Management LLC ADV, Huntington National Bank, AE Wealth Management LLC, Fenimore Asset Management Inc., F3Logic LLC, Livingston Group Asset Management CO operating as Southport Capital Management and West Branch Capital LLC. View Insider Buying and Selling for MCCORMICK & CO /SH.

How do I buy shares of MCCORMICK & CO /SH?

Shares of MKC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MCCORMICK & CO /SH's stock price today?

One share of MKC stock can currently be purchased for approximately $172.96.

How big of a company is MCCORMICK & CO /SH?

MCCORMICK & CO /SH has a market capitalization of $22.99 billion and generates $5.41 billion in revenue each year. The company earns $933.40 million in net income (profit) each year or $4.97 on an earnings per share basis. MCCORMICK & CO /SH employs 14,400 workers across the globe.View Additional Information About MCCORMICK & CO /SH.

What is MCCORMICK & CO /SH's official website?

The official website for MCCORMICK & CO /SH is http://www.mccormickcorporation.com/.

How can I contact MCCORMICK & CO /SH?

MCCORMICK & CO /SH's mailing address is 24 Schilling Road Suite 1, Hunt Valley MD, 21031. The company can be reached via phone at 410-771-7301 or via email at [email protected]


MarketBeat Community Rating for MCCORMICK & CO /SH (NYSE MKC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  515 (Vote Underperform)
Total Votes:  934
MarketBeat's community ratings are surveys of what our community members think about MCCORMICK & CO /SH and other stocks. Vote "Outperform" if you believe MKC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MKC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel